Personalized mRNA Vaccines for Cancer Patients

Vision: To deliver personalized precision (n=1) mRNA cancer vaccine immunotherapies for Cancer Patients in the Belgium, in cooperation with Institut de Cancérologie Arsène Burny (ICAB) CHU de Liège and LégiaPark, Wallonia.

Our Mission

To help cancer patients. Consistently help Beligium patients to beat the “mean survival” for their cancer, with our 2 core products.

To Beat Cancer. Cancer will emerge in 1 of 2 people within their lifetime. Cancer is a tragic disease which causes pain, misery and death. Cancer costs the Belgium Government and Society over 2.4 billion per annum.

Targeted

Normax Belgium investigational mRNA cancer vaccines will be manufactured for individuals based on the specific molecular features of their tumors which are called neoantigens. Training your immune system to recognize these neoantigen protein targets on the surface of your cancer cells could empower your body to control your cancer.

Personalized

For more than a decade, cancer researchers have been developing a type of treatment known as a personalized cancer vaccine using various technologies, including mRNA and protein fragments, or peptides to target your neoantigens of your cancer. A personalized mRNA vaccine from Normax UK could be a safe and effective tool for your doctors to use in the arsenal to fight your cancer.

Rapid Delivery

Normax Belgium plans to produce a personalized mRNA cancer vaccine for you, after tissue samples have been collected, within 1 to 2 months. Speed is especially important for individualized cancer vaccination. Ideally, a highly individualized vaccine combination to target your neoantigens should be designed and produced within 10 weeks of taking your tumor biopsy and blood sample.

Partnership with

Institut de Cancérologie Arsène Burny

The ICAB of the CHU of Liège strives to offer excellent care to people with cancer, from diagnosis of the disease to returning home, as part of a high-quality, person-centered multidisciplinary approach.

Partnership with LégiaPark

LégiaPark is a business centre dedicated to hosting businesses that operate in life sciences. It’s the ideal location for developing research, production or sales and marketing in optimum conditions right in the heart of a structural ecosystem.

mRNA CANCER VACCINE TECHNOLOGY

Step 1

Identifying the unique mutations of your cancer by comparing the differences of the DNA sequences of your cancer cells and your normal cells.

Step 2

Selecting and testing the patient cancer mutations that could his natural immune system to launch the most effective attack on the cancer cells.

Step 3

Using mRNA vaccine technology to produce the personalized cancer vaccine

mRNA CANCER VACCINE TECHNOLOGY

Clinical Trials

Normax Belgium is initiating clinical trial testing of personalized mRNA vaccines to target individual neoantigens. The goal is a complete and enduring response whereby all signs of the tumor disappear following treatment.

Advanced AI Analytics

The manufacturing process starts with the identification of genetic mutations in a patient’s tumor cells that could give rise to neoantigens. Advanced AI Analytics then predict which neoantigens are most likely to bind to receptors on T cells and stimulate an immune response.

T Cell Education

The vaccine can include genetic sequences for many different neoantigens. The promise of personalized immunotherapy with mRNA vaccines is being able to activate T cells that will specifically recognize individual cancer cells based on their abnormal molecular features.

The Problem: Cancer in Belgium

Cancer Prevalence in Belgium

2021

0
people living with cancer

2025

0
people living with cancer

2030

0
people living with cancer

2040

0
people living with cancer

Cancer Incidence

2022

0
diagnosed with cancer

Cancer Deaths

YEARLY

0
cancer deaths in Belgium

Cancer Economic Cost in Belgium

YEARLY

0

Discover The Future of Personalized Precision Cancer Immunotherapy